Ovarian cancer treatment has been rejuvenated in recent years by the introduction of the PARP inhibitors, starting in relapsed disease for patients with BRCA mutations. Now, sponsors are tackling ovarian cancer in earlier stages with the goal of boosting initial remissions.
The pace of research in ovarian cancer has accelerated in the past few years – moving beyond BRCA and beyond monotherapy toward earlier lines of disease and "smart combinations," in...
Current Treatment Options
In addition to mainstay treatment with platinum-based chemotherapy, three PARP inhibitors are approved as monotherapy second-line maintenance treatments for recurrent ovarian cancer that is still responsive to platinum-based...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
